Clinical trial · Observational
Jejunoileal vs Gastric GIST in the Era of Imatinib.
Characteristics and Prognosis of Jejunoileal Gastrointestinal Stromal Tumors (GISTs) in the Era of Imatinib. A Comparative Retrospective Study With Gastric GISTs.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Introduction: Gastrointestinal Stromal Tumors (GISTs) located in the jejunum or ileum (JI-GIST) are considered of worse prognosis compared to other locations. It has been suggested that this dogma should be revised. The aim of this study is to describe the characteristics of jejunoileal GISTs and its prognosis; and to compare them with gastric GISTs in the era of imatinib. Patients and methods: We retrospectively reviewed the clinical histories of all the patients diagnosed with GISTs between January 2000 and November 2016. Clinical and pathological data, as well recurrence, metastatic, disease-free survival (DFS) as overall (OS) rates of patients with JI-GIST or gastric GIST (G-GIST) were collected and compared.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Disease-free Survival | — | UNRESOLVED | — |
| Overall Survival | — | UNRESOLVED | — |
| Recurrence | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- JI-GIST
- description
- The series comprises 77 patients, of which 29 (37.7%) were located in the jejunum or ileum (JI-GIST).
- label
- G-GIST
- description
- The series comprises 77 patients, of which 48 (62.3%) were located in the stomach (G-GIST).
Primary outcomes (7)
- measure
- KIT Gene mutation
- timeFrame
- 15 years
- description
- Number of patients with a molecular analysis positive for KIT mutation
- measure
- PDGFRA Gene mutation
- timeFrame
- 15 years
- description
- Number of patients with a molecular analysis positive for PDGFRA mutation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Any kind of primary mesenchymal tumor of the gastrointestinal tract with a histomorphological and immunohistochemical (CD117 (+) and/or DOG1 (+)) profile consistent with GIST. Exclusion Criteria: \-
References
Publications (0)
Data not yet available